BioMarck Pharmaceuticals has secured a patent for the key proprietary technology that is at the core of its first potential product.
The U.S. Paten Office granted BioMarck the intellectual property protection for its “methods and compositions for alternating mucus secretion.”
BioMarck is testing a treatment for respiratory diseases based on technology that it has licensed from North Carolina State. The treatment is designed to combat mucus. The firm is also seeking patent coverage in Europe.
According to BioMarck, there are no drugs that treat pulmonary disease by targeting the excessive mucus secretion.
“BioMarck believes that this patent significantly strengthens its overall intellectual property portfolio,” said Indu Parikh, BioMarck’s president and chief scientific officer. ”Our treatment is designed to address a variety of pulmonary diseases, including COPD, asthma and chronic rhinitis, and possibly sinusitis and cystic fibrosis. Each of these market segments has clear needs for a new and effective drug.”
A Phase II clinical trial involving BioMarck’s lead product, an inhalation solution, is scheduled for chronic obstructive pulmonary disease (COPD) for early next year.
The NCSU technology was developed by Kenneth Alder, a processor of cell biology. He is BioMarck’s chief scientist.
